By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Dompe 

Dompe Biogen AG Metallstrasse, 8

6300 - Zug - CH      Switzerland
Phone: 041-7287444 Fax: 041-7287440


SEARCH JOBS








Company News
Dompe Offers A New "Window" On The World Of Scientific Research, With The http://Www.Dompetrials.Com Website, Dedicated To Clinical Trials 12/17/2014 9:51:42 AM
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014 12:21:27 PM
Pharmaceutical Company Dompe Launches REP0112, a Trial to Assess the Efficacy and Safety of Reparixin in Autologous Islet Cell Transplantation 9/26/2013 10:09:32 AM
Dompe Announces the FDA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 9/11/2013 9:21:59 AM
Dompe Announces Innovative Treatment in the Fight Against Type 1 Diabetes: Pancreatic Islet Cell Transplantation, a Hope That Has Already Come True 7/11/2013 10:14:13 AM
Dompe Announces the European Medicines Agency Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 7/1/2013 8:31:07 AM
Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis 2/14/2013 9:52:36 AM
Dompé: The First International Clinical Ophthalmological Trial Concerning Treatment of Neurotrophic Keratitis (NK), an Ocular Pathology With No Cure, Takes Place in Italy 9/7/2012 10:25:56 AM
AAA Acquires Rights to Oncology Antibody Treatment Fabovar from Dompe 8/1/2011 10:02:08 AM
Dyax Corp. (DYAX) Enters into an Exclusive Negotiation Period with Dompe for European License to DX-88 in Angioedema Indications 7/15/2008 6:24:32 AM
12
//-->